Researchers from China Pharmaceutical University and colleagues have provided details on the discovery and preclinical evaluation of [I], a novel stilbene derivative that showed antitumor activity.
Researchers from the Institute of Zoology Guangdong Academy of Sciences have reported on the discovery and preclinical evaluation of a series of diaryl heterocyclic analogues with antiproliferative activities that led to the identification of [I] as the compound with the highest antiproliferative activity, yielding IC50 values of 2.65 μM against HCT-116 colon cancer cell lines comparable to combretastatin A-4 (Ca-4), a tubulin inhibitor with potent anticancer activities.
CEO Mitchell Steiner said Veru Inc. at first downplayed the prospects of oncology candidate VERU-111 in COVID-19 treatment but now, with positive phase II data in hand, the company has a moral obligation to push onward to late-stage research.